Nifedipine Soft Gel Capsules
Heritage Pharmaceuticals Inc
Procardia (Pfizer, Inc)
Heritage Pharmaceuticals Inc announces the immediate availability of nifedipine soft gel capsules, an AB-rated generic equivalent of Pfizer Inc’s Procardia. It is indicated for the treatment of vasospastic angina and chronic stable angina, high blood pressure, and abnormal heart rhythms. The recommended dose is 1 capsule 3 times a day, with 10 mg as the recommended starting dose. Patients should be advised against taking the medicine with grapefruit juice.
Soft gel capsules: 10 and 20 mg
For More Information: www.heritagepharma.com
Teva Pharmaceutical Industries Ltd
Zemplar (AbbVie Inc)
Teva Pharmaceutical Industries Ltd announces the launch of paricalcitol capsules, the generic equivalent of Zemplar tablets in the United States. Paricalcitol capsules are an active form of vitamin D used to treat and prevent secondary hyperparathyroidism in patients with stage 3 or stage 4 chronic kidney disease and in stage 5 patients on dialysis. Information on dosage and administration can be found in the full prescribing information.
Capsules: 1, 2, and 4 mcg
For More Information: www.tevagenerics.com
Acamprosate Calcium Delayed-Release Tablets
InnoPharma Inc and Glenmark Pharmaceuticals Inc
Campral Delayed Release Tablets (Forest Laboratories)
InnoPharma Inc announces the launch of acamprosate calcium delayed-release tablets, a generic equivalent of Forest Laboratories’ Campral delayed-release tablets. InnoPharma has developed the generic formulation of acamprosate calcium delayed-release tablets and entered into an agreement with Glenmark Pharmaceuticals Inc, pursuant to which Glenmark will sell, market, and distribute acamprosate in the United States.
Tablets: 333 mg
For More Information: www.innopharmainc.com
Azacitidine for Injection
VIDAZA (Celgene Corporation)
Sandoz has launched azacitidine for injection, an authorized generic version of Celgene’s VIDAZA. It is indicated for the treatment of myelodysplastic syndrome, a bone disease formerly known as pre-leukemia, including refractory anemia, refractory anemia with ringed sideroblasts if accompanied by neutropenia or thrombocytopenia or requiring transfusions, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia. The recommended starting dose for the first treatment cycle is azacitidine for injection 75 mg/m2
for 7 days to be administered subcutaneously or intravenously.
Injection: 100-mg single-use vials
For More Information: http://www.us.sandoz.com/